Trends in UK cancer trials: results from the UK Coordinating Committee for Cancer Research National Register of Cancer Trials by Vale, C et al.
Trends in UK cancer trials: results from the UK Coordinating
Committee for Cancer Research National Register of Cancer
Trials
C Vale*,1, L Stewart
1 and J Tierney
1
1Meta-analysis Group, MRC Clinical Trials Unit, 222 Euston Road, London NW1 2DA, UK
We aimed to study trends in the design and conduct of randomised controlled trials (RCTs) in cancer in the UK, using the UK
Coordinating Committee for Cancer Research (UKCCCR) National Register of Cancer Trials (NRCT). We conducted a descriptive
survey of 520 UK RCTs in cancer that were registered on the UKCCCR NRCT. All trials had been initiated between 1971 and 2000.
Trials on the NRCT have been conducted in a wide variety of cancer types, but with a third in breast (22%) or lung cancer (11%).
They have largely been funded by the UK public and charity sectors. Overall, there has been a sustained rise in the total numbers of
patients entering UK cancer trials over time with a trend towards larger, multicentre trials, greater recruitment targets and a marked
reduction in the average time taken to complete trials. Trends in the design and conduct of noncommercial cancer RCTs from 1971
to 2000 are encouraging. It will be interesting to see how they develop in light of the implementation of recent national initiatives
regarding cancer clinical trials in the UK.
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The recent report of the Academy of Medical Sciences (AMS)
highlighted a decline in clinical research being conducted through
the NHS (Bell, 2003). Furthermore, Chalmers et al (2003) showed
that across health care, funding for noncommercial clinical trials
had declined with the result that fewer trials were funded in 2002
than during the mid-1990s. There had been no accompanying
increase in the planned size of these trials or the numbers of
patients entering trials in this period. This is in spite of the
commitments made as part of the NHS Plan (NHS Plan for
England, 2000) to increase the proportion of NHS patients treated
in the context of randomised controlled trials (RCTs).
However, an earlier review of published MRC-funded RCTs in
solid tumours conducted between 1962 and 1995 suggested
improved prospects for cancer RCTs (Machin et al, 1997). The
authors recommended that there should be a move towards large-
scale, multicentre collaborative RCTs in all types of cancer. To
assess whether these recommendations had been widely realised
and to explore whether the patterns identified by Chalmers et al
(2003) were true in oncology, we investigated cancer trials
assimilated on the the UK Coordinating Committee for Cancer
Research (UKCCCR) National Register of Cancer Trials (NRCT)
(Fayers, 1995; Fayers et al, 1995; Grosse et al, 1998). As it is a
prospective trial register, the NRCT incorporates trials that failed
to reach full recruitment or did not result in publication as well as
those that were successfully completed. Data are therefore free
from publication bias and other forms of selective reporting biases.
Thus, we aimed to establish information concerning the ‘epide-
miology’ of UK RCTs in cancer and to establish a baseline with
which to compare future trends.
MATERIALS AND METHODS
Since 1997, registration of UK RCTs in all types of cancer on the
UKCCCR NRCT has been actively managed through the Meta-
analysis Group of the MRC Clinical Trials Unit. This is achieved
through contacts established across UK trials centres such that
trials are registered at (or soon after) their inception. Trialists
register information on each trial such that we collect a ‘core’ data
set for each trial. This includes, for example, an ID number, the
trial objectives, eligibility criteria, the main outcome(s), recruit-
ment targets and contact details for the main trial personnel. This
summary information can be registered either on-line (via the
NRCT website) or by submitting paper registration forms or
supplying a trial protocol to the register manager. The trial
summaries provided are then verified prior to being made
available through the NRCT website. Trial records are stored in
a relational Access database and all trial protocols are kept on file.
For this study, appropriate data were exported from the main
register database into SPSS or Excel spreadsheets for further
manipulation and analysis.
By grouping trials together in 5-year cohorts from 1971 to 2000,
based on the date that patient recruitment began, we could
examine whether trial characteristics had changed over time and
investigate any changes that were observed. We planned to explore
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sthe numbers of trials opening overall and by disease site, by single
centre or multiple centres and by funding sources. We also looked
at the planned and actual recruitment of patients into these trials
within these time periods and examined whether the actual accrual
met the targets.
RESULTS
The trials
In all, 610 RCTs are registered on the NRCT. However, trials
initiated between 1962 and 1970 (n¼11) and those initiated post-
2000 (n¼22), as well as those that had been registered but had not
yet begun recruitment (n¼3) were excluded from these analyses.
We also excluded any trials where data on the date recruitment
started, the disease site, the funding source or whether it had been
conducted at a single centre or multiple centres was missing
(n¼54). These exclusions meant that all analyses could be based
on the same subset of 520 trials (85% of the total) on the register,
initiated in 5-year cohorts from 1971 to 2000.
The trials were conducted in a variety of different types of
cancer (Figure 1), with breast cancer being the most frequent (114
trials), almost double that of lung cancer (59 trials), which was the
next most common. Between 20 and 50 trials had looked at
interventions for leukaemia, lymphoma, colorectal, ovarian,
stomach and prostate cancer. In addition, a small number of trials
have been conducted in a range of other cancer types including
cancer of the endometrium/uterus (two trials), kidney (nine trials)
and pancreas (five trials), soft tissue sarcoma (three trials) and
melanoma (five trials).
The largest funders of trials recorded on the UKCCCR NRCT
were the UK Medical Research Council (MRC), who funded 30% of
all trials, and Cancer Research UK (formerly the Cancer Research
Campaign and the Imperial Cancer Research Fund), who funded a
further 27%. The next largest funders were the pharmaceutical
industry (17%), charities other than CRUK (14%) and the NHS/
DoH (7%). The majority of the trials were multicentre (83%), and
over time, the proportion of single-centre trials conducted in the
UK has fallen dramatically from 40% in the 1971–1975 cohort
down to only 5% in the 1996–2000 cohort (Figure 2). Figure 2
shows a steady rise in the numbers of new trials opening from the
1971–1975 cohort until 1991–1995 cohort, from 27 to 134.
However, this fell to 95 new trials for the 1996–2000 cohort.
Further investigation of this decline suggests that it is largely due
to changes in one large trial centre in the UK (MRC Clinical Trials
Unit). The number of new randomised trials conducted by this
group fell from 25 in the period 1991–1995 to 10 in 1996–2000.
Trial size and recruitment
For these analyses, we further limited the trial subset to those
where the completion dates/final number of patients (completed
trials) or the current date/current number of patients (ongoing
trials) were known. The resulting sample included 404 trials, 71 of
which were ongoing. The median target recruitment for these 404
trials was 328 patients (range 200–460) and the sum total of target
recruitment for all trials has increased steadily over time (Figure 3).
Further investigation of this trend showed that it is influenced by
two distinct factors: firstly, an increase in the overall number of
trials conducted (Figure 2) and, secondly, an increase in the
numbers of trials with the largest recruitment targets. Figure 4
shows that in the 1996–2000 cohort, more than 40% of all trials
aimed to recruit 500 or more participants compared with 0% of
trials in the 1971–1975 cohort.
For the 333 trials that had completed recruitment, just under
half (48%) reached or exceeded the planned size, 19% of all trials
recruited at least 75% of the planned numbers of patients, while
20% recruited less than 25% of the planned number of patients.
Figure 5 shows the relationship between the sum of the target
numbers for all trials and the actual recruitment over time. It can
be seen from this plot that although the target for trials that
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Figure 1 Number of trials registered per disease area.
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Figure 2 Number of trials opening per cohort (by 5-year period),
showing proportions of single- and multiple-centre trials.
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sopened in the period 1991–1995 was the largest, at slightly below
55000 patients, the actual number of patients recruited into trials
in this cohort was similar to that of the previous cohort (1986–
1990) at around 40000 patients. Figure 6 shows that the mean
number of patients recruited per trial per year has increased over
time, from 65 patients (1971–1975) up to 197 patients (1996–
2000). The impact of this increased recruitment rate has been that
even with increases in trial size, the time taken to complete
recruitment has fallen, such that the median duration of trials that
recruited at least 90% of the target had fallen from 7.2 years
(1971–1975) to 2.7 years (1996–2000).
DISCUSSION
The UKCCCR NRCT is the longest-established prospective cancer
trials register in the UK. However, there is no compulsion for trials
in the UK to be routinely registered and so, although extensive, the
UKCCCR NRCT is not fully comprehensive. The majority of
pharmaceutical companies do not routinely register their trials and
hence we currently have no way to ascertain what proportion of
commercial RCTs is represented in the NRCT. There are
potentially many more commercial trials in the UK than are
recorded here. Similarly, although it conducts trials through
centres in the UK, the European Organisation for the Research and
Treatment of Cancer (EORTC) does not routinely register its trials
on the UKCCCR NRCT. The NRCT should therefore only be
considered representative of publicly funded and charity funded
UK trials. It is also possible that the trials we do not identify and
register are those being conducted in isolation in academic
departments or clinics. This could have introduced some bias
into these results since these are possibly the more poorly
resourced, smaller-scale, single-centre trials. Furthermore, these
trials may be likely to have lower rates of recruitment than those
conducted through established networks of clinicians and
hospitals. Nevertheless, the UKCCCR NRCT has provided a unique
and useful tool to monitor trends in UK noncommercial RCTs in
cancer over the last 30 years. Trials on the NRCT have been
conducted in a wide variety of cancer types, although almost a
third of these trials have been in either breast cancer or lung
cancer. Overall, there has been a sustained rise in the total
numbers of patients entering UK cancer trials over time with a
trend towards larger, multicentre trials, greater recruitment targets
and, importantly, a marked reduction in the average time taken to
complete recruitment to trials.
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Figure 3 Target recruitment (sum) for trials opening within 5-year
cohorts.
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Figure 4 Target recruitment for trials opening within 5-year cohorts.
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Figure 5 Actual and target accrual (sum) by 5-year cohort. NB. Accrual
for the 1996–2000 cohort appears low as many of the larger trials in this
cohort are ongoing and are therefore excluded from this analysis.
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Figure 6 Trial recruitment rate per year (mean7s.d.) for trials opening
in 5-year cohorts.
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sLike Chalmers et al (2003), our findings showed that the number
of new trials being initiated rose steadily from the early 1970s to a
peak in the mid-1990s. However, in cancer, although fewer trials
were initiated in the final cohort (1996–2000), the overall planned
recruitment continued to increase. Furthermore, the average
duration of trials steadily decreased as the rate of recruitment
into trials rose to maximum in the 1996–2000 cohort. Since RCTs
in cancer dominate the noncommercial sector, our data could
imply that the true decline in other areas of health care may, in
fact, be more acute than reported previously (Bell, 2003; Chalmers
et al, 2003).
For cancer, our results show moves towards larger, multicentre
collaborative group trials, possibly representative of the strong
base for cancer clinical trials in the UK. They demonstrate an
encouraging baseline, particularly bearing in mind that they
predate current initiatives to improve the infrastructure for cancer
clinical trials within the NHS, notably the formation of the
National Cancer Research Institute (NCRI) and the National
Cancer Research Network (NCRN). The original aim of the NCRN
to double the numbers of cancer patients being treated in clinical
trials by 2006 has already been achieved, suggesting that
potentially more cancer patients are already being treated in the
context of RCTs. The newly established UK Clinical Research
Collaboration (UKCRC) aims to set up research networks in
Alzheimers’ disease, diabetes, mental health, stroke and childrens’
medicine (Coombes, 2004). These should positively influence
clinical research in these areas and help to reverse the trends
recently identified (Bell, 2003; Chalmers et al, 2003).
It will be interesting and important to revisit these analyses to
find out the full influence of the NCRI and NCRN initiatives on UK
RCTs in cancer, and furthermore, to investigate whether recent
legislative changes (European Union Directive, 2001; The medi-
cines for human use (clinical trials) regulations, 2004) and the
response to the MRC Clinical Trials for Tomorrow review (Medical
Research Council, 2003) have impacted on these trends.
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